Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rac-Vorozole SCHEMBL13223107 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Vorozole SCHEMBL29363602 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| [N-Methyl-11C]Vorozole SCHEMBL12171619 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Rac-Vorozole SCHEMBL29606650 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Rac-Vorozole SCHEMBL1552681 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B1 | |
| Vorozole SCHEMBL19127035 | 0.92 | CYP19A1 (0.84) | CYP19A1CYP11B1 | |
| SCHEMBL13223109 | 0.91 | CYP19A1 (0.83) | CYP19A1CYP11B1 | |
| SCHEMBL13223108 | 0.91 | CYP19A1 (0.83) | CYP19A1CYP11B1 | |
| SCHEMBL3871739 | 0.86 | CYP19A1 (0.76) | CYP19A1CYP11B1 | |
| Oxalic Acid SCHEMBL9524494 | 0.84 | CYP19A1 (0.72) | CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 30870 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3645742-B1 | ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4712980-A1 | TREATMENT OF BREAST TISSUE | Havah Therapeutics Pty Ltd (AU) | 2026-03-25 | — | — | EP | claimed |
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | CKP THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4653019-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| WO-2000043553-A1 | IDENTIFYING, MONITORING, AND TREATING WOMEN FOR BREAST PRECANCER OR CANCER | PRO-DUCT HEALTH, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6020327-A | Control of hair growth | THE CENTRAL SHEFFIELD UNIVERSITY HOSPITALS NHS TRUST (GB) | 2000-02-01 | — | — | US | claimed |
| US-5972921-A | UROGENITAL DISORDERS IN MALES | HORMOS MEDICAL OY LTD. (FI) | 1999-10-26 | — | — | US | claimed |
| WO-1999030708-A2 | USE OF AN AROMATASE INHIBITOR IN THE TREATMENT OF DECREASED ANDROGEN TO ESTROGEN RATIO AND DETRUSOR URETHRAL SPHINCTER DYSSYNERGIA IN MEN AND METHOD TO STUDY THE DYSSYNERGIA IN MALE RODENTS | HORMOS MEDICAL OY LTD. (FI) | 1999-06-24 | — | — | WO | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| US-5861389-A | TREATING MALE MENOPAUSE | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-19 | — | — | US | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1997006788-A1 | TRANSDERMAL ADMINISTRATION OF VOROZOLE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-02-27 | — | — | WO | claimed |